Amryt Pharma Plc

Canaccord Genuity Acted as a Co-Agent in a Private Placement for Amryt Pharma plc

Transaction Overview:
Amryt Pharma plc (the “Company”) (Nasdaq: AMYT, AIM: AMYT), priced its $40.0 million private placement on December 8, 2020 at a price of $12.50 per ADS. The Company issued 3,200,000 American Depositary Shares (“ADSs”), each which represent five ordinary shares of Amryt. Proceeds from the private placement will be used for working capital and general corporate purposes, as well as to potentially acquire, in-license or invest in rare disease technologies, products, businesses or assets.

Company Overview:
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Amryt’s commercial business comprises two orphan disease products.